Leading Mid-Corporates of India 2021

16 Experts' View Leading Mid-Corporates of India 2021 What are some of the key products/ services offered by the company? What are some of the key milestones of the company in recent years? In India, BDR is recognized as one of the leading generic manufacturers, producing complex first generic pharmaceutical products. The company has launched over 30 first generic products over the last decade. Embarking on the principles of advanced R&D, BDR has developed a 5,000 sq./mtr State- of- the art R&D facility at Halol in Gujarat. The facility has 100+ scientists, scalable up to 250, and can develop/produce complex formulations like Microsphere, Liposomal, Nanoparticle, Lyophilised Water Soluble Complex, Sustained Released, Extended Release, IR- Solid/Liquid (tablets (sublingual/chewable/ ODR), semi-solid and topical dosage forms. BDR's approach to business differs from those of other major competitors in India. We are always guided by the twin philosophy of “affordability and accessibility” to secure and help save millions of lives around the world. We pursue illness patterns and seek out novel drugs which are complex technologies and further strive to incrementally innovate multiple factors tobringmore sophisticated medicines to market at a reasonable cost. Some of the company's key products like Liposomal Amphotericin B, Caspofungin, Nab-Paclitaxel, Nintedanib, Rucaparib, Abiraterone, Enzalutamide and Rucaaparib BDR Pharmaceuticals Internationals Private Limited Dharmesh Shah Chairman & MD havebeenor arebeingbackward integrated with API, making the company's business model robust and cost-competitive, further emphasizing the two mantras of affordability and accessibility. Themost recentmilestone for the company has been the inauguration of its state of art pharmaceutical production facility in Halol, which will enable the company to expand its capacity and offer critical services such as contract research and manufacturing with some of the most qualified industry professionals. What challenges did your company face during the pandemic? What modernization techniques did your company embrace to steer through the crisis? The epidemic was an unexpected setback for the world, leading to a shortage of raw materials and hurdles in logistical operations of imports and exports. But with the government's help and the ministry of external affairs, we held our ground while competing on a global platform. As the world came to a halt, we never went into a lockdown as we were entrusted to serve mankind and produce essential medicines for COVID-19. However, maintaining a balance by arranging for contract labor in the factory to ensure the ground level operations are not staggered was difficult. We adopted modern techniques to steer through the crisis to expedite product development, by working at the newly developed infrastructure, using the R&D center, for developments of COVID medicines in record time. We inculcated digital transformation while working on a remote work set-up where people can work from home without disturbing the work culture, and thus the business. We also focused on developing key technologies like Water-soluble complexes, Depot Injections, Nano-Particle formulations, delayed releases, extended releases, soft gel capsules, and bilingual capsules. What is your outlook on the Indian pharmaceutical sector? What is your company's growth strategy for the next 3-5 years? The Indian pharmaceutical sector looks promising, as the industry proved itself by standing tall during the pandemic by manufacturing and delivering various critical and life-saving products in record time to the benefit of the countrymen and people at large globally. The pandemic has taught us to be self-reliant by developing specialty chemicals and API, not to depend on other countries for key materials, and expanding our control on the entire value chain and supply chain. We have always prioritized becoming a forward-backward integrated player both from an API standpoint and manufacturing KSM in-house. We also aim to enter the regulatedmarkets where BDR has not been present so far, by building one of the largest oncology API facilities and becoming a global and local manufacturer for oncology API. Lastly, we aim to enter the biosimilar markets in a strategic manner by targeting to develop and partnering with existing players to bring a new dimension to the current markets with innovative products. Dun & Bradstreet